ImClone News
Most Popular ImClone Story
Biogen Idec in play after Icahn makes his move
Biotech powerhouse Biogen Idec has brought in some of Wall Streets top dealmakers to explore a possible sale of the company, which would fetch well over $20 billion. In fact, says Biogen Idec, the... Read more...
Latest Headlines
- January 14, 2009
- October 15, 2008
- October 6, 2008
- October 3, 2008
- October 2, 2008
- October 1, 2008
- September 29, 2008
- September 24, 2008
- September 23, 2008
- September 16, 2008
- September 12, 2008
- September 11, 2008
- September 10, 2008
- August 28, 2008
- August 21, 2008
- August 15, 2008
- August 11, 2008
- August 4, 2008
- July 31, 2008
- June 4, 2008
Paid Research Reports
- The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses
- New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency
- Stakeholder Opinions: Vaccine antigen delivery technologies - Molecular systems to open new markets
- The Top 10 Contract Research Organizations
- Stakeholder Opinions: Vaccine administration technologies - Beyond needles
- Future Pharmaceutical Industry Trends: Long-term opportunities tempered by short-term challenges
